Advances in Chronic Kidney Disease
Volume 15, Issue 4 , Pages 338-346 , October 2008

New Insights Into Stroke in Chronic Kidney Disease

  • Sami L. Khella

      Affiliations

    • Corresponding Author InformationAddress correspondence to Sami L. Khella, MD, Department of Neurology, MOB, Suite 320, Penn Presbyterian Medical Center, 39th and Market Street, Philadelphia, PA 19104.

References 

  1. Khella SL, Bleicher MB. Stroke and its prevention in chronic kidney disease. Clin J Am Soc Nephrol. 2007;2:1343–1351
  2. Bos MJ, Koudstaal PJ, Hofman A, et al. Decreased glomerular filtration rate is a risk factor for hemorrhagic but not for ischemic stroke. The Rotterdam Study. Stroke. 2007;38:3127
  3. Koren-Morag N, Goldbourt U, Tanne D. Renal dysfunction and risk of ischemic stroke or TIA in patients with cardiovascular disease. Neurology. 2006;67:224–228
  4. Weiner DE, Tighiouart H, Amin MG, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: A pooled analysis of community-based studies. J Am Soc Nephrol. 2004;15:1307–1315
  5. Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351:1285–1295
  6. McCullough PA, Li S, Jurkovitz CT, et al. Chronic kidney disease and cardiovascular disease in volunteer and randomly selected populations: KEEP and NHANES. Am J Kidney Dis. 2008;51:B68–B68
  7. Weiner DE, Tighiouart H, Stark PC. Kidney disease is a risk factor for recurrent cardiovascular disease and mortality. Am J Kidney Dis. 2004;44:198–206
  8. Abramson JL, Jurkvitz CT, Vaccarino V, et al. Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: The ARIC study. Kidney Int. 2003;64:610–615
  9. Nakayama M, Metoki H, Terawak H, et al. Kidney dysfunction as a risk factor for first symptomatic stroke events in a general Japanese population—The Ohasama study. Nephrol Dial Transplant. 2007;22:1910–1915
  10. van der Sande FM, Hermans MM, Leunissen KM, et al. Noncardiac consequences of hypertension in hemodialysis patients. Semin Dial. 2004;17:304–306
  11. Aull-Watschinger S, Konstantin H, Demetriou D, et al. Pre-transplant predictors of cerebrovascular events after kidney transplantation. Nephrol Dial Transplant. 2007;23:1429–1435
  12. Oliveras A, Roquer J, Puig JM, et al. Stroke in renal transplant recipients: Epidemiology, predictive risk factors and outcome. Clin Transplant. 2003;17:1–8
  13. Caplan LR, Gorelick P, Hier D. Race, sex, and occlusive cerebrovascular disease: A review. Stroke. 1986;17:648–655
  14. Mohr JP, Caplan LR, Melski JW. The Harvard Cooperative Stroke Registry: A prospective registry. Neurology. 1978;28:754–762
  15. Seliger SL, Gillen DL, Longstreth WT, et al. Elevated risk of stroke among patients with end-stage renal disease. Kidney Int. 2003;64:603–609
  16. Toyoda K, Fujii K, Fujimi S, et al. Stroke in patients on maintenance hemodialysis: A 22-year single-center study. Am J Kidney Dis. 2005;45:1058–1066
  17. Savitz SI, Caplan LR. Vertebrobasilar disease. N Engl J Med. 2005;352:2618–2626
  18. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981–2987
  19. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA. 1997;277:739–745
  20. The Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145–153
  21. Hansson L, Lithell H, Skoog I, et al. Study on cognition and prognosis in the elderly (SCOPE): Principal results of a randomized double-blind intervention trial. Blood Press. 1999;8:177–183
  22. Bosch J, Yusuf S, Pogue J, et al. Use of ramipril in preventing stroke: Double blind randomised trial. BMJ. 2002;324:699–702
  23. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21:875–886
  24. Staessen JA, Wang JG. Birkenhäger WH: Outcome beyond blood pressure control?. Eur Heart J. 2003;24:504–514
  25. Weiner DE, Tighiouart H, Levey AS, et al. Lowest systolic blood pressure is associated with stroke in stages 3 to 4 chronic kidney disease. J Am Soc Nephrol. 2007;18:960–966
  26. Ninomiya T, Perkovic V, Gallagher M, et al. Lower blood pressure and risk of recurrent stroke in patients with chronic kidney disease: PROGRESS trial. Kidney Int. 2008;73:963–970
  27. Committee Progress Management: PROGRESS–Perindopril Protection Against Recurrent Stroke Study: Characteristics of the study population at baseline. J Hypertens. 1999;17:1647–1645
  28. Steinmetz OM, Panzer U, Stahl RAK, et al. Statin therapy in patients with chronic kidney disease: To use or not to use. Eur J Clin Invest. 2006;36:519–527
  29. Bianchi S, Bigazzi R, Caiazza A, et al. A controlled prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis. 2003;41:565–570
  30. Wanner C, Krane V, März W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238–248
  31. Fellstrom B, Holdaas H, Jardine AG, et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients: Baseline data from the AURORA Study. Kidney Blood Press Res. 2007;30:314–322
  32. Baigent C, Landray M, Leaper C, et al. First United Kingdom Heart and Renal Protection (UK-HARP-I) Study: Biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis. 2005;45:473–484
  33. Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int. 2003;84:S207–S210
  34. The Canadian Cooperative Study Group: A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med. 1978;299:53–59
  35. Bousser MG, Eschwege E, Haguenau M, et al. “AICLA” controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke. 1983;14:4–14
  36. Farrell B, Godwin J, Richards S, et al. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: Final results. J Neurol Neurosurg Psychiatry. 1991;54:1044–1054
  37. The SALT Collaborative Group: Swedish aspirin low-dose trial (SALT) of 75 mg of aspirin as secondary prophylaxis after cerebral vascular ischemic events. Lancet. 1991;338:1345–1349
  38. Van Gijn J, Algra A. Secondary stroke prevention with antithrombotic drugs: What to do next?. Cerebrovasc Dis. 1997;7:30–32
  39. Algra A, van Gijn J. Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin. J Neurol Neurosurg Psychiatry. 1996;66:197–199
  40. Collaboration Antithrombotic Trialists: Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2000;324:71–86
  41. Gorelick P, Weisman S. Risk of hemorrhagic stroke with aspirin use. An update. Stroke. 2005;36:1801–1807
  42. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348:1329–1339
  43. Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study: 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143:1–13
  44. Kaufman JS, O'Connor TZ, Zhang JH, et al. Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. J Am Soc Nephrol. 2003;14:2313–2321
  45. Best PJM, Steinhubl SR, Berger PB, et al. The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: Results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J. 2008;155:687–693
  46. Diener HC, Cunha L, Forbes C, et al. European stroke prevention study: 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143:1–13
  47. Gent M, Blakely JA, Easton JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet. 1989;1:1215–1220
  48. Rothwell PM, Eliasziw M, Gutnikov SA, et al. Carotid Endarterectomy Trialists' Collaboration. Analysis of pooled data from the randomised controlled trials of endarterectomy for symptomatic carotid stenosis. Lancet. 2003;361:107–116
  49. Barnett HJ, Taylor DW, Eliasziw M, et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med. 1998;339:1415–1425
  50. Tarakji A, McConaughy A, Nicholas GG. The risk of carotid endarterectomy in patients with chronic renal insufficiency, current surgery. J Vasc Surg. 2006;63:326–329
  51. Ascher E, Marks NA, Schulzer RW, et al. Carotid endarterectomy in patients with chronic renal insufficiency: A recent series of 184 cases. J Vasc Surg. 2005;41:24–29
  52. Stoner MC, Abbott WM, Wong DR, et al. Defining the high-risk patient for carotid endarterectomy: An analysis of the prospective National Surgical Quality Improvement Program database. J Vasc Surg. 2006;43:285–295
  53. Mathew A, Devereaux PJ, O'Hare A, et al. Chronic kidney disease and postoperative mortality: A systematic review and meta-analysis. Kidney Int. 2008;73:1069–1081
  54. Debing E, Van den Brande P. Chronic renal insufficiency and risk of early mortality in patients undergoing carotid endarterectomy. Ann Vasc Surg. 2006;20:609–613
  55. Mas JL, Chatellier G, Beyssen B, et al. Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. N Engl J Med. 2006;355:1660–1671
  56. Yadav JS, Wholey MH, Kuntz RE, et al. Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med. 2004;351:1493–1501
  57. Bogousslavsky J, Cachin C, Regli F, et al. Cardiac sources of embolism and cerebral infarction-clinical consequences and vascular concomitants: The Lausanne Stroke Registry. Neurology. 1991;41:855–859
  58. Kittner SJ, Sharkness CM, Price TR, et al. Infarcts with a cardiac source of embolism in NINCDS Stroke Data Bank: historical features. Neurology. 1990;40:281–284
  59. Vázquez E, Sánchez-Perales C, Borrego F, et al. Influence of atrial fibrillation on the morbido-mortality of patients on hemodialysis. Am Heart J. 2000;140:886–890
  60. Genovesi S, Pogliani D, Faini A, et al. Prevalence of atrial fibrillation and associated factors in a population of long-term hemodialysis patients. Am J Kidney Dis. 2005;46:897–902
  61. Weisholzer M, Harm F, Tomasec G, et al. Incidence of stroke among chronic hemodialysis patients with nonrheumatic atrial fibrillation. Am J Nephrol. 2001;21:35–39
  62. Harnett JD, Foley RN, Kent GM, et al. Congestive heart failure in dialysis patients: Prevalence, incidence, prognosis, and risk factors. Kidney Int. 1993;47:884–890
  63. Fabbian F, Catalano C, Lambertini D, et al. Clinical characteristics associated to atrial fibrillation in chronic hemodialysis patients. Clin Nephrol. 2000;54:234–239
  64. Vasquez E, Sanchez-Perales C, Lozano C, et al. Comparison of prognostic value of atrial fibrillation versus sinus rhythm in patients on long-term hemodialysis. Am J Cardiol. 2003;92:868–871
  65. To AC, Yehia M, Collins JF. Atrial fibrillation in haemodialysis patients: Do the guidelines for anticoagulation apply?. Nephrology. 2007;12:441–447
  66. Stroke prevention in atrial fibrillation study. Final results. Circulation. 1991;84:527–539
  67. Stroke Prevention in Atrial Fibrillation Investigators: Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation. Stroke Prevention in Atrial Fibrillation III randomized clinical trial. Lancet. 1996;348:633–638
  68. European Atrial Fibrillation Trial (EAFT) Study Group: Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet. 1993;342:1255–1262
  69. Stroke Prevention in Atrial Fibrillation Investigators: Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet. 1999;343:687–691
  70. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators: The Boston Area Anticoagulation Trial for Atrial Fibrillation: The effect of low-dose warfarin on the risk of stoke in patients with nonrheumatic atrial fibrillation. N Engl J Med. 1990;323:1505–1511
  71. Koos R, Mahnken AH, Mühlenbruch G, et al. Relation of oral antiboagulation to cardiac valvular and coronary calcium assessed by multislice spiral computed tomography. Am J Cardiol. 2005;96:747–749
  72. Coates T, Kirkland GS, Dymock RB, et al. Cutaneous necrosis from calcific uremic arteriolopathy. Am J Kidney Dis. 1998;32:384–391
  73. Bazari H, Jaff MR, Mannstadt M, et al. Case 7-2007—A 59-year-old woman with diabetic renal disease and nonhealing skin ulcers. N Engl J Med. 2007;356:1049–1057

 Supported in part by Harry & Joan Kahn Fund.

PII: S1548-5595(08)00105-5

doi: 10.1053/j.ackd.2008.07.002

Advances in Chronic Kidney Disease
Volume 15, Issue 4 , Pages 338-346 , October 2008

Article Tools

* Image Usage & Resolution